Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.

摘要: Cytochrome P450 (CYP) 2D6 is one of the most highly active, oxidative and polymorphic enzymes known to metabolize Parkinsonian toxins clinically established anti-Parkinson's disease (PD) drugs. Albeit CYP2D6 gene not present in rodents, its orthologs perform almost similar function with imprecise substrate inhibitor specificity. expression catalytic activity are found be regulated at every stage central dogma except replication as well epigenetic level. codes for a set alternate splice variants that give rise range possessing variable activity. Case-control studies, meta-analysis systemic reviews covering polymorphism PD risk have demonstrated poor metabolizer phenotype possesses considerable genetic susceptibility. Besides, ultra-rapid offers protection against some populations while lack positive or inverse association also reported other inhabitants. polymorphisms resulting into deviant protein products differing could lead inter-individual variations, which explained certain extent on basis sample size, life style factors, food habits, ethnicity tools used statistical analysis across various studies. Current article describes role played by metabolism anti-PD drugs/Parkinsonian how determine protection. Moreover, their roles rodent models Parkinsonism been mentioned. Finally, perspective inconsistency findings futuristic relevance diagnosis treatment has highlighted.